^
Association details:
| Biomarker: | PTK7 expression + TROP2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | BCG033 (TROP-2-targeted antibody-drug conjugate, PTK7-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer
Published date:
04/14/2023
Excerpt:
BCG033 candidates showed potent anti-tumor activity in several cell line-derived xenografts including TNBC xenografts, indicating that BCG033 has strong therapeutic potential in TNBC and other PTK7/TROP2 co-expressing cancers. Patient-derived TNBC xenografts with co-expression of PTK7 and TROP2 have been screened for future in vivo drug efficacy screening. In summary, BCG033 has the potential to exert anti-tumor efficacy in TNBC and other solid tumors co-expressing PTK7 and TROP2.
DOI:
https://doi.org/10.1158/1538-7445.AM2023-LB216
